Search

Business development

MSI will build broad usage of the RCATâ„¢ platform and other core technologies through the development of superior diagnostic and genomics tools. To accomplish this, we will pursue vigorous internal development and the establishment of strategic collaborations and licensing agreements to popularize the company's technology base. Amersham Pharmacia Biotech (APB) Partnership MSI will make RCAT widely available to the academic community and industrial scientists for research purposes through a strategic partnership with Amersham Pharmacia Biotech. APB is a major international life sciences company with market leadership position in virtually all of the markets in which it competes. APB's novel systems are used to sequence DNA, uncover the function of genes and proteins, separate biomolecules, screen potential drugs and manufacture biopharmaceuticals. APB will act as MSI's exclusive

distributor for RCAT research reagents. Alliances We are actively pursuing partnerships in the in vitro diagnostic industry as well as key additional strategic areas. These alliances will enable us to rapidly expand the applications for Rolling Circle Amplification Technology and the other technology platforms at Molecular Staging. Financing MSI has received financing from Domain Associates, Biotechnology Investments Limited, and Collinson, Howe & Lennox, LLC as well as from Amersham Pharmacia Biotech. For more information, please contact: Molecular Staging Inc. Business Development 300 George Street info@molecularstaging.com Voice (203)772-5000 FAX (203)776 5276

Leave a Reply